Product CAS No
VELCADE (bortezomib) is a type of chemotherapy called a targeted therapy. VELCADE belongs to a class of medicines called proteasome inhibitors. It is approved by the FDA for the treatment of multiple myeloma and mantle cell lymphoma.
Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow). Bortezomib is also used to treat people with mantle cell lymphoma (fast-growing cancer that begins in the cells of the immune system).